Compare AHMA & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | EDSA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United Arab Emirates | Canada |
| Employees | 44 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1M | 51.6M |
| IPO Year | N/A | 2018 |
| Metric | AHMA | EDSA |
|---|---|---|
| Price | $1.76 | $5.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 49.5K | ★ 53.1K |
| Earning Date | 05-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $0.72 |
| 52 Week High | $39.50 | $20.32 |
| Indicator | AHMA | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 35.78 |
| Support Level | $1.64 | $4.80 |
| Resistance Level | $1.82 | $9.00 |
| Average True Range (ATR) | 0.16 | 0.60 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.69 | 26.19 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.